IL-4 and IL-13 are not involved in IL-31-induced itch-associated scratching behaviour in mice
- PMID: 38855893
- DOI: 10.1111/exd.15115
IL-4 and IL-13 are not involved in IL-31-induced itch-associated scratching behaviour in mice
Abstract
Itchy skin or pruritus is a common cutaneous symptom that causes an urge to scratch, and the role of interleukins (IL) in itchy skin has been widely studied. IL-4 and IL-13 are known to induce chronic itch. Similarly, the direct role of IL-31 in inducing itch has been demonstrated in clinical situations such as atopic dermatitis and prurigo nodularis. Moreover, IL-4 receptor α antibodies (dupilumab) and IL-31 receptor A antibodies (nemolizumab) inhibit pruritus. However, the interplay between these ILs in pruritus remains unclear. Therefore, we investigated the reciprocal effects of these cytokines on pruritus in mice. The intradermal administration of IL-31 induced itch-associated scratching behaviour in a dose-dependent manner. Interestingly, the amount of IL-31 and IL-4/IL-13, co-administration or 30 min pre-administration of IL-4/IL-13 and intradermal or intravenous pre-administration of IL-4 did not affect IL-31-induced itch-associated scratching behaviour when it was observed for 30 min, 2 h, 24 h or 48 h. Pre-administration of neutralising antibodies against IL-4 and IL-13 also did not affect IL-31-induced itch-associated scratching behaviour. These results suggest that IL-31 can induce itching independently of IL-4 and IL-13 in vivo.
Keywords: IL‐13; IL‐31; IL‐4; pruritus.
© 2024 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Similar articles
-
Cynomolgus monkey model of interleukin-31-induced scratching depicts blockade of human interleukin-31 receptor A by a humanized monoclonal antibody.Exp Dermatol. 2018 Jan;27(1):14-21. doi: 10.1111/exd.13236. Epub 2017 Apr 10. Exp Dermatol. 2018. PMID: 27714851
-
Interleukin-4 and interleukin-13 evoke scratching behaviour in mice.Exp Dermatol. 2019 Dec;28(12):1501-1504. doi: 10.1111/exd.14034. Epub 2019 Oct 1. Exp Dermatol. 2019. PMID: 31505056
-
Interleukin Profiling in Atopic Dermatitis and Chronic Nodular Prurigo.Int J Mol Sci. 2024 Aug 2;25(15):8445. doi: 10.3390/ijms25158445. Int J Mol Sci. 2024. PMID: 39126011 Free PMC article.
-
Nemolizumab: An Innovative Biologic Treatment to Control Interleukin 31, a Key Mediator in Atopic Dermatitis and Prurigo Nodularis.Actas Dermosifiliogr. 2022 Jul-Aug;113(7):674-684. doi: 10.1016/j.ad.2021.12.014. Epub 2021 Dec 23. Actas Dermosifiliogr. 2022. PMID: 35842249 Review. English, Spanish.
-
IL-31 Inhibition as a Therapeutic Approach for the Management of Chronic Pruritic Dermatoses.Drugs. 2021 Jun;81(8):895-905. doi: 10.1007/s40265-021-01521-1. Epub 2021 Apr 21. Drugs. 2021. PMID: 33881741
Cited by
-
Macrophages in inflammatory skin diseases and skin tumors.Front Immunol. 2024 Dec 5;15:1430825. doi: 10.3389/fimmu.2024.1430825. eCollection 2024. Front Immunol. 2024. PMID: 39703508 Free PMC article. Review.
-
Four Cases of Prurigo Nodularis Requiring Nemolizumab due to Persistent Pruritus or Lesions after Dupilumab Treatment.Acta Derm Venereol. 2025 Jun 16;105:adv43419. doi: 10.2340/actadv.v105.43419. Acta Derm Venereol. 2025. PMID: 40524402 Free PMC article. No abstract available.
References
REFERENCES
-
- Oetjen LK, Mack MR, Feng J, et al. Sensory neurons Co‐opt classical immune signaling pathways to mediate chronic itch. Cell. 2017;171(1):217‐228 e13. doi:10.1016/j.cell.2017.08.006
-
- Beck LA, Thaci D, Hamilton JD, et al. Dupilumab treatment in adults with moderate‐to‐severe atopic dermatitis. N Engl J Med. 2014;371(2):130‐139. doi:10.1056/NEJMoa1314768
-
- Blauvelt A, de Bruin‐Weller M, Gooderham M, et al. Long‐term management of moderate‐to‐severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1‐year, randomised, double‐blinded, placebo‐controlled, phase 3 trial. Lancet. 2017;389(10086):2287‐2303. doi:10.1016/S0140-6736(17)31191-1
-
- Zhai LL, Savage KT, Qiu CC, Jin A, Valdes‐Rodriguez R, Mollanazar NK. Chronic pruritus responding to Dupilumab—a case series. Medicines (Basel). 2019;6(3):72. doi:10.3390/medicines6030072
-
- Campion M, Smith L, Gatault S, Metais C, Buddenkotte J, Steinhoff M. Interleukin‐4 and interleukin‐13 evoke scratching behaviour in mice. Exp Dermatol. 2019;28(12):1501‐1504. doi:10.1111/exd.14034
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials